- Home
- PMEC vs NRXP Comparison
PMEC vs NRXP Comparison
Compare PMEC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- NRXP
- Stock Information
- Founded
- PMEC 1984
- NRXP 2015
- Country
- PMEC Singapore
- NRXP United States
- Employees
- PMEC N/A
- NRXP N/A
- Industry
- PMEC
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- PMEC
- NRXP Health Care
- Exchange
- PMEC Nasdaq
- NRXP Nasdaq
- Market Cap
- PMEC 23.4M
- NRXP 21.6M
- IPO Year
- PMEC 2023
- NRXP N/A
- Fundamental
- Price
- PMEC $0.61
- NRXP $1.64
- Analyst Decision
- PMEC
- NRXP Strong Buy
- Analyst Count
- PMEC 0
- NRXP 2
- Target Price
- PMEC N/A
- NRXP $31.00
- AVG Volume (30 Days)
- PMEC 86.1K
- NRXP 86.1K
- Earning Date
- PMEC 09-26-2024
- NRXP 08-14-2024
- Dividend Yield
- PMEC N/A
- NRXP N/A
- EPS Growth
- PMEC N/A
- NRXP N/A
- EPS
- PMEC N/A
- NRXP N/A
- Revenue
- PMEC $72,524,000.00
- NRXP N/A
- Revenue This Year
- PMEC N/A
- NRXP N/A
- Revenue Next Year
- PMEC N/A
- NRXP N/A
- P/E Ratio
- PMEC N/A
- NRXP N/A
- Revenue Growth
- PMEC 5.07
- NRXP N/A
- 52 Week Low
- PMEC $0.49
- NRXP $1.59
- 52 Week High
- PMEC $4.18
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- PMEC 47.55
- NRXP 34.23
- Support Level
- PMEC $0.58
- NRXP $1.82
- Resistance Level
- PMEC $0.68
- NRXP $1.91
- Average True Range (ATR)
- PMEC 0.05
- NRXP 0.13
- MACD
- PMEC -0.01
- NRXP -0.01
- Stochastic Oscillator
- PMEC 32.38
- NRXP 9.09
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.